CETI's focus is to treat and repurpose a substantial amount of the water it receives from oil fields. Posttreatment, this water can be reused by oil companies, in agriculture, or even as drinking water where needed. Globally, agriculture consumes about 70% of freshwater resources, making CETI's water remediation capabilities particularly valuable to local communities and Industries. ABOUT CYBER ENVIRO-TECH, INC. CETI is an international eco-conscious, oil/sludge, water and soil remediation Company. Using bi ...

CETI's proprietary products and systems utilize environmentally friendly biologics which negate the need for chemical inputs and create a simpler process which reduces operational costs and initial capital outlay. In addition, CETI's water remediation approach has a much higher Standard Removal Proficiency by achieving 100% removal efficiency, far exceeding alternative approaches like ADS/DEP. These traditional processes only reach an approximate 43% removal, or 66% with more chemicals. "I find myself inund ...

MINNEAPOLIS, May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor conferences: About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of spe ...

ST. PAUL, Minn., May 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced the launch of the G-Rex® Grant Program, a $20 million initiative to propel the advancement of cell and gene therapies (CGT). The G-Rex® Grant Program will provide academic and commercial institutions engaged in IND enabling preclinical research, process development, and/or ongoing GMP manufacturing of cell and gene therapies with the ...

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal ...

MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADP ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jur ...

Financial Data and Key Metrics - Q3 revenue was $303.4 million, a 2% year-over-year increase on an organic basis and a 3% increase on a reported basis [30] - Adjusted EPS was $0.48 compared to $0.53 in the prior year quarter, with foreign exchange having a material impact on EPS [30] - Adjusted operating margin increased sequentially by 290 basis points to 33% [15] - Cash generated from operations in the quarter was $81 million, with net investment in capital expenditures at $16.4 million [34] Business Line Performance - Protein Sciences segment revenue declined 1% year-over-year on an organic basis, reflecting stabilization in biopharma and Chinese end markets [22] - Diagnostics and Genomics segment reported 10% organic growth, with spatial biology and molecular diagnostics leading the way [46][80] - GMP reagents business achieved a new quarterly record with over 40% growth [25] - ExoDx Prostate test volume grew over 25% in Q3 [48] Market Performance - North America improved sequentially with low single-digit year-over-year growth, driven by strong performance in cell and gene therapy [41] - Europe declined mid-single digits due to challenging comps from mid-teens growth in the prior year [41] - China saw mid-single-digit revenue decline, but stabilization was observed, with early signs of improvement [20][21] Strategic Direction and Industry Competition - The company is leveraging AI to create new patentable, hyperactive designer proteins and reagents [9] - The Ella platform received ISO 13485 Certification, opening up clinical diagnostic opportunities [24] - The company is investing in scaling up production capacity for the Comet platform to meet growing demand [47][105] Management Commentary on Operating Environment and Future Outlook - Management noted stabilization in biopharma and China markets, with early indications of improvement in the back half of the calendar year [29] - The company expects Q4 to look similar to Q3, with incremental sequential improvement in revenue and adjusted operating margins [36] - Long-term confidence in China as the fastest-growing major region for life science tools, though the path to accelerated growth may take longer than previous cycles [53] Other Important Information - The company received two awards from CiteAb, including the ELISA Kit Supplier of the Year and an Innovation Award for RNAscope HiPlex 12 [16][8] - The company is on track to launch RNAscope HiPlex Pro on the Comet platform by the end of the fiscal year [27] Q&A Session Summary Question: Outlook for high single-digit or 10%+ organic growth in FY2025 [59] - Management believes the company will outperform the market, potentially reaching high single-digit or double-digit growth when markets return to mid-single-digit growth rates [60][83] Question: Biopharma funding and cell and gene therapy growth [61] - Early-stage funding is expected to flow into consumables first, with a delay of about two quarters before impacting the business [61] - Cell and gene therapy growth is sustainable, with GMP reagents growing over 40% in Q3 [62] Question: Impact of the expanded Fisher agreement in Europe [68] - The agreement is expected to enhance customer reach and convenience, similar to the successful U.S. distribution agreement [70][97] Question: Production capacity for the Comet platform [77] - Production constraints are expected to be resolved by the first fiscal quarter of 2025, with demand outpacing initial projections [105] Question: Margin outlook for Q4 and FY2025 [93] - Management aims to achieve mid-30s operating margin by the end of FY2024, with incremental improvement expected in Q4 [94] Question: Academic end market outlook [137] - The academic market remains stable, with continued growth expected in spatial biology and proteomic tools [145] Question: Competitive wins for Lunaphore and spatial biology market [139] - The Comet platform is seeing competitive wins due to its automation and workflow advantages [140] Question: ProteinSimple business growth [148] - The Simple Western platform grew double digits in both instruments and consumables, with strong performance in cell and gene therapy applications [114] Question: GMP facility capacity [150] - Capacity for GMP proteins is no longer an issue, with sufficient capacity expected to last for a decade or more [150]

Exhibit 99.1 BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2024 RESULTS Minneapolis/May 1, 2024/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2024. Third Quarter FY2024 Highlights ●Third quarter organic revenue increased by 2% (3% reported) to $303.4 million. ●GAAP earnings per share (EPS) was $0.31 versus $0.43 one year ago. Delivered adjusted EPS of $0.48 compared to $0.53 one year ago. ●Strong commercial execution in Diagnostics & Genomics l ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other ...